Want to see HK:2297 full AI Analyst Report?
2297 Stock Chart & Stats
HK$0.26
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$0.26
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$0.14 - HK$0.37
Previous CloseN/A
Volume40.00K
Average Volume (3M)178.03K
Market Cap
HK$210.20M
Enterprise ValueHK$374.62
Total Cash (Recent Filing)HK$129.01M
Total Debt (Recent Filing)HK$181.94M
Price to Earnings (P/E)―
Beta0.82
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding1,401,358,800
10 Day Avg. Volume175,500
30 Day Avg. Volume178,033
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.88
Price to Sales (P/S)16.34
P/FCF Ratio-3.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Modest LeverageThe currently modest debt burden provides some financial flexibility compared with a highly leveraged medical-device business. Lower leverage can reduce financing pressure and leave more capacity to support operations, product development, or market expansion if performance improves.
Reduced Cash BurnThe smaller cash outflow in 2025 indicates some improvement in cash discipline compared with the prior year. If this direction continues, it could extend liquidity and reduce funding pressure, although the company has not yet reached self-funding capability.
Losses Below Prior PeaksA reduction in losses from the 2021–2022 extremes suggests that the company has moved away from its most severe period of financial deterioration. This offers a foundation for recovery, provided revenue, product economics, and operating performance stabilize.
Bears Say
Sharp Revenue ContractionTwo consecutive years of substantial revenue contraction point to weakened commercial scale and reduced demand or adoption across the business. Persistent top-line decline can dilute operating leverage, limit reinvestment, and make a durable return to profitability more difficult.
Negative Product EconomicsNegative gross margin means reported sales did not cover the direct cost of products in 2025, a serious challenge for a device-and-consumables model. Unless product economics recover, additional revenue may fail to improve earnings and could increase cash losses.
Persistent Cash BurnRepeatedly negative operating and free cash flow shows that the company has not funded its operations and investment internally over an extended period. Continued cash burn can consume balance-sheet resources and increase reliance on external funding to sustain the business.
Rainmed Medical Limited News
2297 FAQ
What was Rainmed Medical Limited’s price range in the past 12 months?
Rainmed Medical Limited lowest stock price was HK$0.14 and its highest was HK$0.36 in the past 12 months.
What is Rainmed Medical Limited’s market cap?
Rainmed Medical Limited’s market cap is HK$210.20M.
When is Rainmed Medical Limited’s upcoming earnings report date?
Rainmed Medical Limited’s upcoming earnings report date is Apr 01, 2027 which is in 183 days.
How were Rainmed Medical Limited’s earnings last quarter?
Rainmed Medical Limited released its earnings results on Aug 31, 2026. The company reported -HK$0.019 earnings per share for the quarter.
Is Rainmed Medical Limited overvalued?
According to Wall Street analysts Rainmed Medical Limited’s price is currently Overvalued.
Does Rainmed Medical Limited pay dividends?
Rainmed Medical Limited does not currently pay dividends.
What is Rainmed Medical Limited’s EPS estimate?
Rainmed Medical Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rainmed Medical Limited have?
Rainmed Medical Limited has 1,401,358,800 shares outstanding.
What happened to Rainmed Medical Limited’s price movement after its last earnings report?
Rainmed Medical Limited reported an EPS of -HK$0.019 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Rainmed Medical Limited?
Currently, no hedge funds are holding shares in HK:2297
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Rainmed Medical Limited
Rainmed Medical Limited is a medical technology firm specializing in the creation, development, and market launch of advanced systems that utilize coronary angiography to assess fractional flow reserve (FFR) and the index of microvascular resistance (IMR). Its offerings include the FlashAngio caFFR System, which accurately determines FFR values by reconstructing a three-dimensional model of the coronary arterial system from two angiographic images. Additionally, the company provides the FlashAngio caIMR System, an innovative non-invasive solution for the diagnosis and treatment of microcirculatory lesions. Rainmed Medical is also engaged in pioneering intelligent angiographic injection technologies, robotic navigation systems for vascular interventions, and flash renal denervation solutions. Established in 2014, the company is headquartered in Suzhou, China.
Technical Analysis
Acotec Scientific Holdings Limited
―
Vincent Medical Holdings Limited
―
Broncus Holding Corp.
―
MicroTech Medical (Hangzhou) Co., Ltd. Class H
―
Venus Medtech (Hangzhou), Inc. Class H
―